Noa Schwartz1, Beatrice Goilav, Chaim Putterman. 1. aDepartment of Medicine, Montefiore Medical Center bPediatric Nephrology, The Children's Hospital at Montefiore, Albert Einstein College of Medicine cDivision of Rheumatology, Department of Medicine dDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA *Noa Schwartz and Beatrice Goilav contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis. RECENT FINDINGS: Localized long-lived plasma cells have been identified as playing an important role in lupus nephritis. In addition, the roles of aberrant expression of microRNAs and proinflammatory cytokines have been explored. Early diagnosis is important for effective treatment and multiple biomarkers have been identified; however, none has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than each individual component. Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for nonrenal systemic lupus erythematosus. Rituximab has not proven itself in large, placebo-controlled trials, although it is still being used in refractory cases of lupus nephritis. SUMMARY: Lupus nephritis is a potentially devastating complication of systemic lupus erythematosus. Immune cells, cytokines, and epigenetic factors have all been recently implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease.
PURPOSE OF REVIEW: Renal involvement is a major cause of morbidity and mortality in systemic lupus erythematosus. In this review, we provide an update on recent discoveries in the pathogenesis, diagnosis, and treatment of lupus nephritis. RECENT FINDINGS: Localized long-lived plasma cells have been identified as playing an important role in lupus nephritis. In addition, the roles of aberrant expression of microRNAs and proinflammatory cytokines have been explored. Early diagnosis is important for effective treatment and multiple biomarkers have been identified; however, none has been yet validated for clinical use. Biomarker panels may turn out to be more accurate than each individual component. Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for nonrenal systemic lupus erythematosus. Rituximab has not proven itself in large, placebo-controlled trials, although it is still being used in refractory cases of lupus nephritis. SUMMARY:Lupus nephritis is a potentially devastating complication of systemic lupus erythematosus. Immune cells, cytokines, and epigenetic factors have all been recently implicated in lupus nephritis pathogenesis. These recent discoveries may enable a paradigm shift in the treatment of this complex disease, allowing the tailoring of treatment to target specific pathogenic mediators at specific points in time in the progression of disease.
Authors: Robert Biesen; Cemal Demir; Fidan Barkhudarova; Joachim R Grün; Marta Steinbrich-Zöllner; Marina Backhaus; Thomas Häupl; Martin Rudwaleit; Gabriela Riemekasten; Andreas Radbruch; Falk Hiepe; Gerd-Rüdiger Burmester; Andreas Grützkau Journal: Arthritis Rheum Date: 2008-04
Authors: Jeannie L Te; Igor M Dozmorov; Joel M Guthridge; Kim L Nguyen; Joshua W Cavett; Jennifer A Kelly; Gail R Bruner; John B Harley; Joshua O Ojwang Journal: PLoS One Date: 2010-05-11 Impact factor: 3.240
Authors: D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy Journal: Blood Date: 1994-10-15 Impact factor: 22.113
Authors: Èlia Ripoll; Ana Merino; Immaculada Herrero-Fresneda; Josep M Aran; Montse Goma; Nuria Bolaños; Laura de Ramon; Oriol Bestard; Josep M Cruzado; Josep M Grinyó; Juan Torras Journal: PLoS One Date: 2013-06-14 Impact factor: 3.240
Authors: Patrick Coit; Paul Renauer; Matlock A Jeffries; Joan T Merrill; W Joseph McCune; Kathleen Maksimowicz-McKinnon; Amr H Sawalha Journal: J Autoimmun Date: 2015-05-23 Impact factor: 7.094
Authors: Sonya VanPatten; Shan Sun; Mingzhu He; Kai Fan Cheng; Ahmad Altiti; Angelos Papatheodorou; Czeslawa Kowal; Venkatesh Jeganathan; James M Crawford; Ona Bloom; Bruce T Volpe; Christian Grant; Nathalie Meurice; Thomas R Coleman; Betty Diamond; Yousef Al-Abed Journal: J Med Chem Date: 2016-09-20 Impact factor: 7.446
Authors: K Hudspeth; S Wang; J Wang; S Rahman; M A Smith; K A Casey; Z Manna; M Sanjuan; R Kolbeck; S Hasni; R Ettinger; R M Siegel Journal: Clin Exp Immunol Date: 2019-03-19 Impact factor: 4.330